NCT01603212View on ClinicalTrials.gov

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 18, 2013

Primary Completion Date

July 5, 2017

Study Completion Date

July 5, 2017

Conditions
Melanoma
Interventions
DRUG

Vemurafenib

"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."

DRUG

IL-2

"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."

DRUG

Interferon Alpha-2b

5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01603212 - Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | Biotech Hunter | Biotech Hunter